Targeting lncRNA PVT1/miR-145-5p/ABCC-1 Pathway Enhances Paclitaxel Sensitivity and Suppresses Melanoma Progression

Background

As a highly aggressive type of skin cancer, melanoma cells show significant resistance against a variety of chemotherapeutics, such as paclitaxel, which limits the efficacy of the treatment. Studies have highlighted the potential role of noncoding RNA dysregulation in melanoma, affecting tumor progression and drug response, including lncRNA PVT1.